FLT1 Antibodies

Structure of FLT1

Vascular endothelial growth factor receptor 1 encoded by the FLT1 gene is a type I transmembrane glycoprotein with a molecular weight of approximately 180 kDa. Its actual molecular weight fluctuates within the range of 150-180 kDa depending on the degree of glycosylation. The extracellular domain of this protein contains seven immunoglobulin-like domains (D1-D7), which are key regions for ligand binding. The D2 domain plays a core role in binding to VEGF-A, while the D3 domain is crucial for the binding of PIGF. Its intracellular part is composed of the perimembrane region, the split tyrosine kinase domain (separated by the kinase insertion region between TK1 and TK2), and the C-terminal tail. FLT1 exerts a unique negative regulatory function by generating a soluble splicing variant (sFLT1, approximately 100 kDa) lacking intracellular kinase domains, a characteristic that is of great significance in placental vascular physiology and the pathological mechanism of preeclampsia.

Fig. 1 Genomic structure of the FLT1 upstream region.¹

Key structural properties of FLT1:

• Extracellular ligand binding domain
• Unique kinase regulation mechanism
• Transmembrane negative regulatory function
• Structure-function adaptability

Functions of FLT1

The core function of FLT1 (VEGFR1) is to regulate angiogenesis and homeostasis, and it also plays a complex role in various pathophysiological processes.

Compared with the potent pro-angiogenic signals mediated by VEGFR2, the signal output of FLT1 is usually weaker and more context-dependent, reflecting its unique role in vascular biology as a precise "regulatory valve" rather than a simple "switch".

Applications of FLT1 and FLT1 Antibody in Literature

1. Tai, Yifan, et al. "FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer." EMBO Molecular Medicine 16.8 (2024): 1957-1980. https://doi.org/10.1038/s44321-024-00094-2

This study found that FLT1 drives the development of PARP inhibitor resistance in BRCA1/2 mutant breast cancer and protects tumor cells through non-classical pathways. Blocking FLT1 can inhibit AKT and enhance CD8+ T cell infiltration, thereby restoring sensitivity to the resistant tumors, making it a potential therapeutic target.

2. Ashar-Patel, Ami, et al. "FLT1 and transcriptome-wide polyadenylation site (PAS) analysis in preeclampsia." Scientific reports 7.1 (2017): 12139. https://doi.org/10.1038/s41598-017-11639-6

Studies have confirmed that the Flt1 gene is significantly upregulated in both early-onset and late-onset preeclampsia placental tissues. Its mRNA level is directly correlated with the increase in maternal blood pressure, suggesting that it could be a potential target for RNAi therapy.

3. Wujcicka, Wioletta Izabela, et al. "Single nucleotide polymorphisms from CSF2, FLT1, TFPI and TLR9 genes are associated with prelabor rupture of membranes." Genes 12.11 (2021): 1725. https://doi.org/10.3390/genes12111725

This study analyzed 360 pregnant women and found that the polymorphisms of genes related to hemostasis and angiogenesis (such as FLT1, etc.) acting together could affect the risk of premature rupture of membranes, but the single gene polymorphism of FLT1 had no independent association.

4. Raikwar, Nandita S., Kang Z. Liu, and Christie P. Thomas. "N-terminal cleavage and release of the ectodomain of Flt1 is mediated via ADAM10 and ADAM 17 and regulated by VEGFR2 and the Flt1 intracellular domain." PloS one 9.11 (2014): e112794. https://doi.org/10.1371/journal.pone.0112794

The study found that the Flt1 receptor can be cleaved by the ADAM10/17 proteases, generating fragments that can antagonize VEGF. PKC and the ubiquitination system regulate this cleavage process. The interaction between Flt1 and VEGFR2 affects the cleavage efficiency and the range of action of the fragments.

5. Morris, Brian J., et al. "Vascular endothelial growth factor receptor 1 gene (FLT1) longevity variant increases lifespan by reducing mortality risk posed by hypertension." Aging (Albany NY) 15.10 (2023): 3967. https://doi.org/10.18632/aging.204722

The research has found that a specific genotype (GG) of the longevity gene FLT1 can reduce the risk of death caused by hypertension, thereby prolonging lifespan. However, it has no significant protective effect against coronary heart disease, stroke or diabetes.

Creative Biolabs: FLT1 Antibodies for Research

Creative Biolabs specializes in the production of high-quality FLT1 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom FLT1 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our FLT1 antibodies, custom preparations, or technical support, contact us at email.